Latest Global Manufacturing News

Immutep has struck a strategic licensing deal with Dr. Reddy’s, granting rights to commercialise its novel cancer immunotherapy Eftilagimod Alfa across key emerging markets. The agreement includes a $20 million upfront payment and potential milestones exceeding $349 million.

6K Additive, Inc. launches a fully underwritten A$48 million IPO on the ASX, aiming to scale its innovative scrap-based metal powder production for additive manufacturing. The capital raise supports a major capacity expansion backed by a US Department of Defense grant.

Papyrus Australia has secured a $4.2 million contract to manufacture biodegradable Collar Keeper® products for the mining sector, marking its shift from R&D to commercial production. The agreement with TBS Mining Solutions sets the stage for sustainable innovation in mining operations.

Orica Limited has delivered its strongest financial performance in over a decade, driven by premium product demand and digital innovation, while advancing ambitious sustainability targets. The company signals continued growth for 2026 despite emerging supply chain challenges.

Orica Limited reported a 6% increase in revenue to AUD 8.14 billion and a 23% rise in EBIT to AUD 992.2 million for FY2025, alongside record safety performance and significant strides in decarbonisation.

Titomic Limited has launched a major European manufacturing hub and a UK subsidiary, secured a $50 million capital raise, and forged strategic partnerships to advance its cold spray additive manufacturing technology.

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.

Arafura Rare Earths has received conditional approval for a US$100 million equity investment from Export Finance Australia, reinforcing the strategic importance of its Nolans Project in Australia’s critical minerals landscape.

Algorae Pharmaceuticals has signed a binding term sheet with India’s Cadila Pharmaceuticals to introduce two generic medicines targeting cardiovascular and metabolic disorders in Australia and New Zealand.

Amaero Ltd has locked in a five-year exclusive agreement to supply spherical refractory and titanium alloy powders to Titomic, bolstering advanced manufacturing capabilities for defense and aerospace sectors.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial expansion and strategic investments in R&D and manufacturing. The company confirms full-year guidance while advancing key clinical trials and product launches.